Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 16/20 | 0.55 |
| ▸ | CHUK | O15111 | 5/20 | 0.55 |
| ▸ | AURKA | O14965 | 1/20 | 0.50 |
| ▸ | FLT3 | P36888 | 1/20 | 0.50 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.50 |
| ▸ | BTK | Q06187 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 2/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3391403 | 0.89 | IKBKB (0.69) | IKBKBCHUKAURKAFLT3CSNK1E | |
| SCHEMBL3392939 | 0.88 | IKBKB (0.56) | IKBKBCHUKAURKAFLT3CSNK1E | |
| SCHEMBL3393169 | 0.87 | IKBKB (0.56) | IKBKBCHUKAURKAFLT3CSNK1E | |
| SCHEMBL3389182 | 0.86 | IKBKB (0.53) | IKBKBCHUKAURKAFLT3CSNK1E | |
| SCHEMBL3395831 | 0.85 | IKBKB (0.53) | IKBKBCHUKAURKAFLT3CSNK1E | |
| SCHEMBL3395968 | 0.84 | IKBKB (0.56) | IKBKBCHUKAURKAFLT3CSNK1E | |
| SCHEMBL552079 | 0.84 | IKBKB (0.79) | IKBKBCHUKAURKAFLT3CSNK1E | |
| SCHEMBL3392308 | 0.83 | IKBKB (0.53) | IKBKBCHUKAURKAFLT3CSNK1E | |
| SCHEMBL3395187 | 0.83 | IKBKB (0.57) | IKBKBCHUKAURKAFLT3CSNK1E | |
| SCHEMBL3396364 | 0.83 | IKBKB (0.54) | IKBKBCHUKAURKAFLT3CSNK1E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501780-B2 | Indazole carboxamides and their use | GLAXOSMITHKLINE LLC (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501780-B2 | Indazole carboxamides and their use | GLAXOSMITHKLINE LLC (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501780-B2 | Indazole carboxamides and their use | GLAXOSMITHKLINE LLC (US) | 2013-08-06 | — | — | US | disclosed |
| EP-1758578-B1 | NOVEL INDAZOLE CARBOXAMIDES AND THEIR USE | GLAXOSMITHKLINE LLC (US) | 2010-12-29 | — | — | EP | disclosed |
| EP-1758578-B1 | NOVEL INDAZOLE CARBOXAMIDES AND THEIR USE | GLAXOSMITHKLINE LLC (US) | 2010-12-29 | — | — | EP | disclosed |
| EP-1758578-A4 | NOVEL INDAZOLE CARBOXAMIDES AND THEIR USE | SMITHKLINE BEECHAM CORP (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20070281933-A1 | Novel Indazole Carboxamides And Their Use | SMITHKLINE BEECHAM CORPORATION (US) | 2007-12-06 | — | — | US | disclosed |
| US-20070281933-A1 | Novel Indazole Carboxamides And Their Use | SMITHKLINE BEECHAM CORPORATION (US) | 2007-12-06 | — | — | US | disclosed |
| US-20070281933-A1 | Novel Indazole Carboxamides And Their Use | SMITHKLINE BEECHAM CORPORATION (US) | 2007-12-06 | — | — | US | disclosed |
| EP-1758578-A2 | NOVEL INDAZOLE CARBOXAMIDES AND THEIR USE | Smithkline Beecham Corporation (US) | 2007-03-07 | — | — | EP | disclosed |
| WO-2006002434-A2 | NOVEL INDAZOLE CARBOXAMIDES AND THEIR USE | SMITHKLINE BEECHAM CORPORATION (US) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281933-A1 | Novel Indazole Carboxamides And Their Use | IKBKG, IRAK2, NFKBIA | IKBKB 8/4885CHUK 9/4885AURKA 642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.